Gland Pharma has appointed Deepak Sapra as its new Chief Executive Officer, effective November 16, 2026. The company’s Board approved the appointment following a recommendation from the Nomination and Remuneration Committee, subject to Sapra’s acceptance of the offer.

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Executive Profile

Deepak Sapra is a seasoned business leader with 27 years of executive experience, including over 23 years in the pharmaceutical industry. He currently serves as the Chief Executive Officer – API and Services at Dr. Reddy’s Laboratories Limited (DRL) and as a Board Member of Aurigene Pharma Services.

In his current role at DRL, Sapra is responsible for global portfolio strategy and leads an integrated B2B business spanning generic pharmaceuticals, CDMO services, APIs, collaborations and alliances, public health, and global patient access. His operations cover key markets including the United States, European Union, Japan, Brazil, China, Mexico, the Middle East, and emerging markets such as Africa.

Professional Background

Sapra’s prior experience includes serving as Chief Executive Officer – Custom Pharmaceutical Services, where he led a global CDMO business serving innovator pharmaceutical companies across the United States, Europe, and Japan. Between 2011 and 2015, he held senior leadership positions as Vice President – Global Generics Business Development and Senior Director – Global Generics Portfolio Management.

His expertise encompasses the end-to-end pharmaceutical value chain, including CDMO partnerships, generics, APIs, sales and marketing, international business management, business development, supply chain management, R&D, operations, portfolio strategy, public health, and access-led partnerships.

Education

Sapra holds a Bachelor's degree in Mechanical Engineering from the Indian Railways Institute of Mechanical and Electrical Engineering, Jamalpur, and a Master's degree in Management from the Indian Institute of Management, Bangalore. He was also a recipient of the Chevening Scholarship at the University of Bradford, UK, and a Fulbright Fellow at Carnegie Mellon University, Pittsburgh, USA.

Gland Pharma reported a robust start to FY27, with consolidated revenue from operations rising 20% year-on-year to ₹18,003 million in the quarter ended June 30, 2026. Profit after tax (PAT) surged 47% to ₹3,170 million, driven by strong demand in its Contract Development and Manufacturing Operations (CDMO) segment and significant volume expansion in key markets like the United States. The company’s EBITDA margin expanded to 27% from 24% in the corresponding quarter of the previous year, reflecting improved operational efficiency. These results were formally communicated to investors through newspaper advertisements in English and Telugu, as mandated by regulatory guidelines.

The Board of Directors, meeting on August 10, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deloitte Haskins & Sells, the statutory auditors, issued an unmodified limited review report on the financial statements prepared in accordance with Ind AS 34. In compliance with Regulation 47 of the same regulations, Gland Pharma notified stakeholders that the results are accessible via a Quick Response (QR) code published alongside the announcement. The documents are also available on the company’s website and the platforms of BSE Limited and National Stock Exchange of India Limited.

Consolidated Financial Performance

Gland Pharma’s top-line growth was supported by equal contributions from its CDMO and B2B businesses, each accounting for 50% of total revenue. The CDMO segment grew 20% YoY to ₹8,915 million, while B2B revenue increased 19% to ₹9,088 million. Adjusted EBITDA, which excludes employee stock option compensation expenses, rose 37% to ₹5,102 million, with an adjusted margin of 28%.

Market and Segment Highlights

The United States remained the largest market, contributing 54% of total revenue with a 32% YoY increase to ₹9,810 million. Growth was fueled by recent product launches, including Dalbavancin and Multi-Vitamin, and volume expansion in existing products such as Enoxaparin and Heparin. Europe saw a 20% revenue rise to ₹3,954 million, driven by CDMO products. Conversely, Other Core Markets (Canada, Australia, New Zealand) declined 28% to ₹534 million due to volume drops in existing products.

Research and development expenses stood at ₹772 million, representing 4% of consolidated revenue. The company launched four new molecules in the USA during the quarter. Regulatory progress included three new Abbreviated New Drug Application (ANDA) filings and seven approvals, bringing the cumulative US ANDA portfolio to 389 filings (342 approved, 47 pending).

Pipeline and Strategic Initiatives

Gland Pharma continues to strengthen its complex injectables pipeline, with six products already launched and three more awaiting approval. Fifteen products are currently in co-development, including seven 505(b)(2) applications and eight ANDAs, with commercialization expected to begin in FY28. The company also filed 21 Ready-to-Use (RTU) infusion bag products, receiving approval for 18 so far; this portfolio addresses an estimated $644 million opportunity in the US market.

Strategic collaborations include a long-term partnership with Neuland Laboratories for sterile API manufacturing of microparticle depot products and an in-licensing agreement with a China-based developer for a niche liposomal product targeting US and European markets. Additionally, a CDMO partnership with a global pharmaceutical company holds an annualized revenue potential of $90–100 million, with revenues expected to commence from calendar year 2029.

What the Numbers Show

The divergence between consolidated PAT growth (47%) and revenue growth (20%) highlights significant operating leverage achieved through scale. While gross profit margins remained stable at 65%, the expansion in EBITDA margins from 24% to 27% indicates effective cost management despite rising employee benefits expenses (up to ₹4,440 million from ₹4,080 million YoY). The strong cash position, with net cash at ₹32,939 million as of June 2026, provides ample liquidity to fund ongoing capital expenditures of ₹1,132 million in Q1FY27 and future pipeline developments.